Susquehanna International Group, LLP Annexon, Inc. Call Options Transaction History

Susquehanna International Group, LLP

10 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q2 2024 Aug 15, 2024	BUY	$4.33 - $6.79 $1.65 Million - $2.59 Million	381,800 Added 519.46%	455,300 $2.23 Million
Q1 2024 May 07, 2024	BUY	$4.03 - $7.81 $221,247 - $428,769	54,900 Added 295.16%	73,500 $526,000
Q4 2023 Feb 14, 2024	SELL	$1.63 - $4.63 $81,011 - $230,111	-49,700 Reduced 72.77%	18,600 $84,000
Q3 2023 Nov 14, 2023	SELL	$2.13 - $3.84 $78,171 - $140,928	-36,700 Reduced 34.95%	68,300 $161,000
Q2 2023 Aug 11, 2023	SELL	$2.1 - $6.37 $108,780 - $329,966	-51,800 Reduced 33.04%	105,000 $369,000
Q1 2023 May 16, 2023	SELL	$3.74 - $7.46 $1.05 Million - $2.09 Million	-280,200 Reduced 64.12%	156,800 $603,000
Q4 2022 Feb 14, 2023	BUY	$4.56 - $6.61 $233,927 - $339,093	51,300 Added 13.3%	437,000 $2.26 Million
Q3 2022 Nov 14, 2022	BUY	$3.75 - $6.63 $547,500 - $967,980	146,000 Added 60.91%	385,700 $2.38 Million
Q2 2022 Aug 15, 2022	BUY	$2.11 - $4.06 $469,897 - $904,161	222,700 Added 1310.0%	239,700 $904,000
Q1 2022 May 16, 2022	BUY	$2.73 - $11.94 $46,410 - $202,980	17,000 New	17,000 $46,000

158

101M

3.61M

1.08M

Ticker ANNX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 47,617,700
Market Cap $332M
Description
Annexon, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapeutics for autoimmune, neurodegenerative, and ophthalmic disorders. The company's C1q is an initiating molecule of the classical complement pathway that targets distinct disease processes, such as antibody-mediated autoimmune disease and complement-mediated n...

Get notified when there are updates to the investment portfolio of Susquehanna International Group, LLP, based on Form 13F filings with the SEC.

Stay updated on Susquehanna International Group, LLP with notifications on news.